New members appointed to the Federal Drug Agency committees

On August 30, 2026, the King signed a royal decree regarding the replacement of members of the Transparency Committee and the Advisory Committee of the Federal Agency for Medicines and Health Products (FAMHP). The text, proposed by the Minister of Public Health F. Vandenbroucke, is published in the Belgian Official Gazette of September 10, 2026, page 49557, under the official reference [C − 2026/006595].

The decree is based notably on the law of July 20, 2006, relating to the creation and operation of the FAMHP (Article 10), on the royal decrees of February 25, 2007, establishing the composition and operation of the Advisory Committee and the Transparency Committee, as well as on the law of July 20, 1990, aimed at promoting the balanced presence of men and women in advisory bodies. The opinion of the Inspector of Finance was given on July 14, 2026.

Transparency Committee

Two replacements are made within the Transparency Committee, for the remaining duration of the mandates, as full members:

• Koen Straetmans is replaced by Hendrik De Rocker, representative of the Belgian Pharmaceutical Association;
• Céline Driessen is replaced by Koen Straetmans, representative of the National Association of Wholesale Distributors.

Advisory Committee

Seven replacements concern the Advisory Committee, for the remaining duration of the mandates:

• Emma Lenom is replaced by Sophie Cors, representative of the Federal Public Service Public Health, Food Chain Safety and Environment, as a full member;
• Yves Van Laethem is replaced by Stijn Boodts, representative of the Superior Health Council, as a full member;
• Fabrice Péters is replaced by Alexandra Couttenier, representative of the Superior Health Council, as a substitute member;
• Ann Verrydt is replaced by Stéphany Janssens, representative of the Office of Cooperative Pharmacies of Belgium, as a substitute member;
• Lieselot De Vos is replaced by Fadoua Amraoui, representative of the Professional Association of Manufacturers, Importers and Distributors of Medical Devices, as a substitute member;
• Céline Driessen is replaced by Koen Straetmans, representative of the National Association of Wholesale Distributors, as a substitute member;
• Leen De Cort is replaced by Abigaël Laame, representative of the Belgian Association for Research and Expertise of Consumer Organizations, as a substitute member.

Entry into force

In accordance with Article 10 of the decree, the text enters into force on the day following its publication in the Belgian Official Gazette, namely September 11, 2026. The Minister responsible for Public Health is charged with the execution of the decree.

These appointments ensure the continuity of the work of the two advisory bodies of the FAMHP, which provide opinions on price transparency and the reimbursement of medicines, as well as on scientific and regulatory issues. For healthcare professionals, manufacturers, and patients, the renewal of these seats guarantees that the expert bodies remain fully operational and representative of the sector’s stakeholders.

Official source: Royal Decree of August 30, 2026, regarding the replacement of members of the Transparency Committee and the Advisory Committee of the Federal Agency for Medicines and Health Products, published in the Belgian Official Gazette of September 10, 2026, page 49557, reference [C − 2026/006595].